Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multitarget regimen for atherosclerotic cerebral small vessel disease
ChiCTR2100049216Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bilobalide, alpha-lipoic acid, coenzyme q10, mecobalamin and idebenone in Cerebral Small Vessel Disease (CSVD), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Montreal Cognitive Assessment score, Gait Scale score and 1 more. Started Aug 2021; status: recruiting.
02
Drugs
bilobalidealpha-lipoic acidcoenzyme q10mecobalaminidebenone
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on ChiCTR2100049216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049216.